Weiguo X. Su

Zhangjiang Hi Tech Park
Zhangjiang, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 66 publications

Safety of fruquintinib mono- and combo therapy in metastatic colorectal cancer: real-world subgroup analysis from China.

Safety of fruquintinib mono- and combo therapy in metastatic colorectal cancer: real-world subgroup analysis from China.

Journal: Future oncology (London, England)

Published: May 28, 2026

Surufatinib plus toripalimab for patients with advanced solid tumors and disease progression after prior immunotherapy: an open-label multi-cohort phase 2 trial.

Surufatinib plus toripalimab for patients with advanced solid tumors and disease progression after prior immunotherapy: an open-label multi-cohort phase 2 trial.

Journal: Cancer immunology, immunotherapy : CII

Published: February 10, 2026

Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study.

Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study.

Journal: The Lancet regional health. Western Pacific

Published: October 30, 2025

Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study.

Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study.

Journal: Communications medicine

Published: September 18, 2025

Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.

Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.

Journal: Lancet (London, England)

Published: June 11, 2025

The effect of cytomegalovirus and EB virus activation on hematopoietic reconstitution after intensive immunosuppressive therapy for severe aplastic anemia

The effect of cytomegalovirus and EB virus activation on hematopoietic reconstitution after intensive immunosuppressive therapy for severe aplastic anemia

Journal: Zhonghua nei ke za zhi

Published: June 08, 2025

Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial.

Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial.

Journal: Nature communications

Published: May 19, 2025

Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study.

Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study.

Journal: EClinicalMedicine

Published: March 29, 2025

Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study.

Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study.

Journal: Therapeutic advances in medical oncology

Published: March 10, 2025

Comparison of the efficacy and safety between high-dose intravenous iron and oral iron in treating iron deficiency anemia: a multicenter, prospective, open-label, randomized controlled study

Comparison of the efficacy and safety between high-dose intravenous iron and oral iron in treating iron deficiency anemia: a multicenter, prospective, open-label, randomized controlled study

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: January 07, 2025

Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p).

Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p).

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 07, 2025

Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment.

Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment.

Journal: ACS medicinal chemistry letters

Published: December 25, 2024

Showing 1-12 of 66

Last Updated: 09/26/2026